Showing 3231-3240 of 5910 results for "".
- MSU Researchers Discover Link Between Cholesterol and Diabetic Retinopathyhttps://modernod.com/news/msu-researchers-discover-link-between-cholesterol-and-diabetic-retinopathy/2481822/Research led by Michigan State and other universities found that diabetes, age-related health conditions, and other metabolic disorders can lead to a buildup of cholesterol in the retina. This tends to crystalize and contribute to the development of diabetic retinopathy. Cryst
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Scientists Develop Therapeutic Model for Potentially Treating Incurable Eye Diseaseshttps://modernod.com/news/scientists-develop-therapeutic-model-for-potentially-treating-incurable-eye-diseases/2481794/Researchers have successfully transplanted human microglia cells into mouse retina to create a model that could be used to test new treatments for retinal and central nervous system diseases, according to not-for-profit eLife. Microglia are the innate immune cells of the cent
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of
- Regeneron Expects FDA Decision on High-Dose Aflibercept in Third Quarterhttps://modernod.com/news/regeneron-expects-fda-decision-on-high-dose-eylea-in-third-quarter/2481766/During its second quarter conference call, Regeneron said it anticipates the FDA will take action on its biologics license application (BLA) for high-dose aflibercept during the third quarter. In June, citing "an ongoing review of inspection findings at a third-party filler,"
- AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107https://modernod.com/news/asclepix-therapeutics-raises-10-million-to-advance-phase-12a-clinical-study-of-axt107/2481749/AsclepiX Therapeutics announced that it has secured a $10 million Series A-3 financing to advance clinical development of its lead candidate, AXT107 (gersizangitide), in patients with wet AMD. “With the completion of this round, we are excited to embark into the next phase of
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Study: Dietary Oral Zeaxanthin Decreases the Progression of Wet AMDhttps://modernod.com/news/study-dietary-oral-zeaxanthin-decreases-the-progression-of-wet-amd/2481741/Data published in the peer-reviewed journal Ophthalmology and Therapy confirmed both an earlier comparative
- Two-Year Results for Aflibercept 8 mg from PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in DMEhttps://modernod.com/news/two-year-results-for-aflibercept-8-mg-from-photon-trial-demonstrate-durable-vision-gains-at-extended-dosing-intervals-in-dme/2481696/Regeneron released on Tuesday topline, 2-year (96 weeks) data for aflibercept 8 mg from the PHOTON trial in patients with diabetic macular edema (DME). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing intervals (after three initial monthly
- Alcon to Showcase Innovations for Eye Care Practice Success at 2023 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-innovations-for-eye-care-practice-success-at-2023-optometrys-meeting/2481682/Alcon will showcase innovations from advances in the reusable lens space to digital offerings at Optometry’s Meeting, the American Optometric Association (AOA) annual conference taking place June 21-24 in Washington, D.C. Through interactive events, Q&A’s, live demonstrations, and